肾小球滤过率斜率对肾脏分层复合终点的贡献
该研究基于CKD试验数据,评估当肾脏分层复合终点(HCE)分析由GFR斜率比较驱动时的临床解读。结果显示,仅用GFR斜率计算的胜算比在DAPA-CKD、CREDENCE、SONAR和ALTITUDE试验中分别为1.44(1.34-1.55)、1.60(1.49-1.72)、1.19(1.10-1.28)和0.82(0.78-0.86),且与完整肾脏HCE(含或不含死亡)的胜算比相似。结论支持将GFR斜率纳入CKD进展HCE,并有助于解读胜算比估计的肾脏HCE治疗效应大小。
要点
- 仅用GFR斜率计算的胜算比与完整肾脏HCE的胜算比相似。
- 不同CKD试验中GFR斜率驱动的胜算比范围从0.82到1.60。
- GFR斜率可纳入CKD进展分层复合终点以解读治疗效应。
核心结论
- 结果支持将GFR斜率纳入CKD进展分层复合终点。
- 有助于解读胜算比估计的肾脏分层复合终点治疗效应大小。
研究设计与样本
- 使用CKD试验数据计算胜算比,比较仅GFR斜率、肾二元事件联合GFR斜率、全因死亡联合肾二元事件及GFR斜率、全因死亡联合肾二元事件等不同组合。
主要发现
- 仅GFR斜率比较的胜算比(95%CI)在DAPA-CKD为1.44(1.34-1.55),CREDENCE为1.60(1.49-1.72),SONAR为1.19(1.10-1.28),ALTITUDE为0.82(0.78-0.86)。
- 仅GFR斜率与完整肾脏HCE(含或不含死亡)的胜算比相似。
临床怎么用
- 在CKD进展分层复合终点分析中可考虑纳入GFR斜率以辅助解读治疗效应。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: A recent chronic kidney disease (CKD) progression hierarchical composite endpoint (HCE) utilizes the glomerular filtration rate (GFR) slope for participants without a dichotomous event. Here, we evaluated clinical interpretations when HCE analyses are driven by GFR slope comparisons. METHODS: Using CKD trial data, we calculated win odds using only GFR slope; dichotomous kidney events and GFR slope; all-cause mortality, dichotomous kidney events, and GFR slope; and all-cause mortality with dichotomous kidney events. RESULTS: Win odds (95% confidence interval) calculated from pairwise GFR slope only comparisons were 1.44 (1.34-1.55), 1.60 (1.49-1.72), 1.19 (1.10-1.28), and 0.82 (0.78-0.86) in the DAPA-CKD, CREDENCE, SONAR, and ALTITUDE trials, respectively. Win odds were similar for the GFR slope only and full kidney HCE with and without mortality. CONCLUSIONS: These results support incorporation of GFR slope into the CKD progression HCE and help to interpret the magnitude of treatment effect on kidney HCE estimated with win odds.
引用
- Little DJ, Jongs N, Brinker M, et al. Contribution of the glomerular filtration rate slope to the kidney hierarchical composite endpoint. Kidney Int. 2025. PMID: 40139566. doi:10.1016/j.kint.2025.03.011
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。